import { EducationalContent } from '../../types';

export const pad: EducationalContent = {
  id: 'pad',
  type: 'concept',
  name: 'Peripheral Artery Disease',
  nameEs: 'Enfermedad Arterial Periferica',
  levels: {
    1: {
      level: 1,
      summary: 'Peripheral artery disease (PAD) is a condition where narrowed arteries reduce blood flow to the legs, causing pain with walking (claudication) and, in severe cases, tissue death (gangrene) that may require amputation.',
      explanation: 'Peripheral artery disease (PAD) is a common circulatory problem in which narrowed arteries reduce blood flow to the limbs, most commonly the legs. It is caused by atherosclerosis, the same process that causes heart attacks and strokes: fatty deposits (plaques) build up inside the artery walls, gradually narrowing the arteries and reducing blood flow. PAD affects about 8-12 million Americans and over 200 million people worldwide. The most common symptom is claudication, which is pain, cramping, or tiredness in the legs that occurs during walking or exercise and goes away with rest. This happens because the narrowed arteries cannot deliver enough blood to meet the increased demand of exercising muscles. Think of it like a garden hose with a kink: when water demand is low, enough gets through, but when you need more water (exercise), the reduced flow becomes noticeable. Many people with PAD have no symptoms at all, or they attribute their leg discomfort to aging. More severe PAD can cause pain even at rest (rest pain), especially at night, and in the worst cases, the reduced blood flow can cause sores that will not heal (ulcers) or tissue death (gangrene), potentially requiring amputation. The ankle-brachial index (ABI) is a simple, painless test used to diagnose PAD. It compares blood pressure at the ankle with blood pressure in the arm. A normal ABI is 1.0-1.3; an ABI less than 0.9 indicates PAD. PAD is a strong marker of systemic atherosclerosis: patients with PAD have a 2-3 times higher risk of heart attack and stroke compared to the general population. Treatment includes lifestyle changes (especially smoking cessation, which is the most important modifiable risk factor), medications, exercise therapy, and in severe cases, procedures to open or bypass the blocked arteries.',
      keyTerms: [
        { term: 'Peripheral artery disease', definition: 'Narrowing of arteries in the legs due to atherosclerosis, reducing blood flow and causing symptoms during walking' },
        { term: 'Claudication', definition: 'Pain, cramping, or fatigue in the legs during walking or exercise that resolves with rest, caused by inadequate blood flow' },
        { term: 'Ankle-brachial index', definition: 'A ratio of blood pressure at the ankle to blood pressure in the arm used to diagnose PAD; less than 0.9 is abnormal' },
        { term: 'Atherosclerosis', definition: 'Buildup of fatty deposits (plaques) inside artery walls that narrows the arteries and reduces blood flow' },
        { term: 'Gangrene', definition: 'Death of body tissue due to severely reduced blood supply, a serious complication of advanced PAD' }
      ],
      clinicalNotes: 'PAD is significantly underdiagnosed. Clinicians should screen high-risk patients (smokers, diabetics, age over 65, age over 50 with risk factors) with ABI measurement. Remember that PAD is a marker of widespread atherosclerosis: these patients need aggressive cardiovascular risk factor management to reduce heart attack and stroke risk, not just treatment of their leg symptoms.'
    },
    2: {
      level: 2,
      summary: 'PAD is classified by the Fontaine and Rutherford systems from asymptomatic to tissue loss. Diagnosis uses ABI and duplex ultrasound. Treatment prioritizes cardiovascular risk reduction, supervised exercise therapy, antiplatelet agents, and cilostazol, with revascularization for critical limb ischemia.',
      explanation: 'PAD severity is classified using two systems. The Fontaine classification: Stage I is asymptomatic, Stage IIa is mild claudication (walking more than 200 meters), Stage IIb is moderate-to-severe claudication (walking less than 200 meters), Stage III is rest pain, and Stage IV is ulceration or gangrene. The Rutherford classification uses categories 0-6 with similar progression. The most clinically important distinction is between claudication (Fontaine II) and critical limb-threatening ischemia (CLTI, Fontaine III-IV), as CLTI requires urgent revascularization to prevent amputation. Diagnosis begins with ABI measurement. ABI less than 0.9 is diagnostic with 95% sensitivity and nearly 100% specificity. ABI interpretation: 0.91-1.30 is normal; 0.71-0.90 is mild PAD; 0.41-0.70 is moderate PAD; 0.40 or less is severe PAD. ABI greater than 1.30 indicates non-compressible calcified vessels (common in diabetes and advanced kidney disease) and is unreliable; toe-brachial index (TBI, normal greater than 0.70) should be used instead. Segmental pressures and pulse volume recordings help localize the level of disease. Duplex ultrasound maps the anatomy and severity of stenoses. CTA and MRA provide detailed anatomic assessment when revascularization is considered. Medical management is the cornerstone and targets both limb symptoms and systemic cardiovascular risk. Antiplatelet therapy (aspirin 75-325 mg or clopidogrel 75 mg) reduces cardiovascular events. The COMPASS trial showed that rivaroxaban 2.5 mg BID plus aspirin reduced major adverse limb events and cardiovascular events compared to aspirin alone in patients with symptomatic PAD. Statin therapy (high-intensity) is indicated for all PAD patients regardless of cholesterol level (cardiovascular risk reduction). Antihypertensive therapy targets less than 130/80 mmHg; beta-blockers are not contraindicated in PAD (a common misconception). Glycemic control in diabetics (HbA1c less than 7%) reduces microvascular disease. Smoking cessation is the single most important intervention: continued smoking doubles amputation risk and halves graft patency. Supervised exercise therapy (SET) is the first-line treatment for claudication: structured walking programs (30-60 minutes per session, 3 times per week, for at least 12 weeks) improve walking distance by 50-200%. SET is as effective as endovascular revascularization for claudication. Cilostazol (a phosphodiesterase III inhibitor) improves walking distance by 40-60% and is the only medication FDA-approved for claudication symptoms. It is contraindicated in heart failure. Revascularization (endovascular or surgical) is reserved for CLTI or lifestyle-limiting claudication refractory to exercise therapy and medical management.',
      keyTerms: [
        { term: 'Critical limb-threatening ischemia', definition: 'The most severe form of PAD with rest pain, non-healing ulcers, or gangrene, requiring urgent revascularization to prevent amputation' },
        { term: 'Fontaine classification', definition: 'A staging system for PAD severity from asymptomatic (Stage I) through tissue loss (Stage IV)' },
        { term: 'Toe-brachial index', definition: 'An alternative to ABI using toe pressure, useful when ankle arteries are non-compressible due to calcification' },
        { term: 'Supervised exercise therapy', definition: 'A structured walking program that is first-line treatment for claudication, improving walking distance by 50-200%' },
        { term: 'Cilostazol', definition: 'A phosphodiesterase III inhibitor that improves walking distance in claudication; the only FDA-approved drug for this indication' },
        { term: 'COMPASS trial', definition: 'A landmark trial showing that rivaroxaban plus aspirin reduces cardiovascular and limb events in PAD compared to aspirin alone' }
      ],
      clinicalNotes: 'Key management pearls: (1) ABI should be measured in both legs; the lower value determines staging. (2) ABI >1.30 is not "super-normal" but indicates calcified vessels and is non-diagnostic; order TBI. (3) Beta-blockers are NOT contraindicated in PAD (debunked myth). (4) Supervised exercise therapy is reimbursed by Medicare and should be prescribed before considering revascularization for claudication. (5) Every PAD patient needs high-intensity statin, antiplatelet, and aggressive risk factor management.'
    },
    3: {
      level: 3,
      summary: 'Comprehensive PAD management integrates anatomic classification for revascularization planning (TASC II), endovascular versus surgical strategies for different arterial segments, wound healing assessment for CLTI, and the WIfI classification system for threatened limbs.',
      explanation: 'Revascularization planning requires understanding PAD anatomy, which is categorized by the affected arterial segment: aortoiliac (inflow), femoropopliteal (outflow), and infrapopliteal (runoff). The TASC II classification grades lesion complexity (A through D) for each segment, where TASC A/B lesions are generally treated endovascularly and TASC C/D lesions may favor surgical bypass, though endovascular techniques have expanded into more complex lesions. For aortoiliac disease, endovascular treatment includes iliac artery stenting (with primary patency rates of 80-90% at 5 years for common iliac lesions). Covered stents (Viabahn, iCAST) may provide better outcomes for long iliac lesions. Surgical options include aortobifemoral bypass (ABF), which has excellent 10-year patency (85-90%) but carries 2-5% operative mortality and is reserved for extensive bilateral disease or failed endovascular treatment. For femoropopliteal disease (the most common location), endovascular options include balloon angioplasty, self-expanding nitinol stents, drug-coated balloons (DCB, paclitaxel-coated), and drug-eluting stents (DES). The IN.PACT Admiral trial demonstrated superior patency for drug-coated balloons compared to plain angioplasty. However, the 2018 Katsanos meta-analysis raised concerns about increased late mortality with paclitaxel-based devices, leading to an FDA review. Subsequent large-scale analyses and the SWEDEPAD trial have largely allayed these concerns, but the debate continues. Surgical bypass using autologous great saphenous vein (GSV) is the gold standard for long femoropopliteal disease, with 5-year primary patency of 65-75% (vein) versus 40-50% (prosthetic PTFE). For infrapopliteal disease (common in diabetics with CLTI), angiosome-directed revascularization targets the specific artery feeding the ischemic territory. The angiosome concept divides the foot into territories supplied by the anterior tibial, posterior tibial, and peroneal arteries. Restoring direct flow to the angiosome containing the wound improves healing. Endovascular treatment of tibial vessels uses plain balloon angioplasty (drug-coated balloons are being studied), and surgical bypass to tibial or pedal arteries uses autologous vein. The WIfI (Wound, Ischemia, and foot Infection) classification system grades CLTI severity using three components: wound depth/extent (0-3), ischemia severity (0-3, based on ABI/toe pressure), and foot infection severity (0-3). The WIfI score predicts amputation risk and helps guide the urgency and type of revascularization. Higher WIfI stages have greater amputation risk and benefit more from revascularization. Wound care in CLTI is equally important as revascularization. Multidisciplinary limb salvage teams (vascular surgeon, podiatrist, wound care specialist, endocrinologist, infectious disease) improve outcomes. Offloading, debridement, infection control, and adequate perfusion are the pillars of diabetic foot ulcer management.',
      keyTerms: [
        { term: 'TASC II classification', definition: 'A system grading PAD lesion complexity (A-D) for aortoiliac and femoropopliteal segments to guide revascularization strategy' },
        { term: 'Drug-coated balloon', definition: 'An angioplasty balloon coated with paclitaxel that inhibits neointimal hyperplasia and improves patency compared to plain angioplasty' },
        { term: 'Angiosome concept', definition: 'A vascular anatomy framework dividing the foot into territories supplied by specific tibial arteries, guiding targeted revascularization for wound healing' },
        { term: 'WIfI classification', definition: 'A staging system for critical limb-threatening ischemia using wound severity, ischemia grade, and foot infection to predict amputation risk' },
        { term: 'Great saphenous vein bypass', definition: 'The gold-standard surgical conduit for infrainguinal bypass, with superior long-term patency compared to prosthetic grafts' },
        { term: 'Neointimal hyperplasia', definition: 'Excessive smooth muscle cell proliferation within a treated artery that causes restenosis after angioplasty or stenting' }
      ],
      clinicalNotes: 'The endovascular-first approach has become dominant for most PAD lesions, but autologous vein bypass remains the gold-standard for long (>25 cm) femoropopliteal occlusions and infrapopliteal disease with suitable vein. Key principle: always preserve the great saphenous vein when possible. If endovascular intervention fails, having an intact GSV provides the best surgical backup. The BEST-CLI trial confirmed that surgical bypass with GSV is superior to endovascular intervention for CLTI in patients with adequate single-segment GSV.'
    },
    4: {
      level: 4,
      summary: 'Advanced PAD management encompasses complex endovascular technologies (atherectomy, intravascular lithotripsy, covered stents), chronic total occlusion crossing techniques, hybrid revascularization strategies, and management of acute limb ischemia.',
      explanation: 'Advanced endovascular technologies for complex PAD include: (1) Atherectomy devices remove plaque rather than displacing it: directional atherectomy (SilverHawk/TurboHawk) excises plaque and is combined with DCB (DEFINITIVE AR trial); orbital atherectomy (Diamondback) sands calcified plaque using an orbiting crown; rotational atherectomy (Jetstream, Phoenix) fragments and aspirates plaque; and laser atherectomy (excimer laser) ablates plaque photochemically. Atherectomy is primarily used for heavily calcified lesions where balloon angioplasty alone cannot achieve adequate lumen gain. (2) Intravascular lithotripsy (IVL, Shockwave) uses sonic pressure waves to fracture calcium within the vessel wall, enabling balloon expansion without the need for atherectomy. This technology has shown excellent safety and efficacy for severely calcified femoropopliteal and iliac lesions (DISRUPT PAD trials). (3) Covered stent-grafts (Viabahn) are used for long femoropopliteal lesions and are the treatment of choice for aneurysmal popliteal artery disease. The VIASTAR trial showed improved patency compared to bare metal stents for long SFA lesions. (4) Bioresorbable scaffolds are under investigation to provide temporary scaffolding without permanent metallic implants. Chronic total occlusions (CTOs) of the femoropopliteal segment present technical challenges. Crossing strategies include: intraluminal (wire through the true lumen of the occluded segment), subintimal angioplasty (SAFARI technique: intentional entry into the subintimal space, crossing beneath the occlusion, and re-entry into the true lumen using a re-entry device such as the Outback catheter or PIONEER catheter), and retrograde/pedal access (when antegrade crossing fails, access the tibial or pedal artery and cross the CTO retrograde). Hybrid revascularization combines open surgical and endovascular techniques in a single procedure. Common hybrid approaches include: iliac stenting with femoral endarterectomy (addressing both inflow and outflow in one session), femoral endarterectomy with SFA stenting, and surgical bypass combined with tibial angioplasty. These are performed in hybrid operating suites equipped with both surgical and fluoroscopic capabilities. Acute limb ischemia (ALI) is a vascular emergency requiring urgent intervention within 6 hours to prevent irreversible tissue loss. Presentation follows the "6 Ps": Pain, Pallor, Pulselessness, Poikilothermia (cold), Paresthesias, and Paralysis. The Rutherford classification of ALI: Class I is viable (no sensory/motor loss), Class IIa is marginally threatened (sensory loss only), Class IIb is immediately threatened (motor loss), and Class III is irreversible (profound sensory/motor loss, muscle rigor). Class I is treated with anticoagulation and elective revascularization; Class IIa/IIb requires urgent revascularization (catheter-directed thrombolysis, percutaneous mechanical thrombectomy, or surgical thromboembolectomy); Class III requires primary amputation. Post-thrombolysis, the underlying lesion (stenosis or aneurysm causing embolization) must be treated. Reperfusion injury (compartment syndrome) requires monitoring and possible fasciotomy. Heparin anticoagulation is initiated immediately upon diagnosis.',
      keyTerms: [
        { term: 'Intravascular lithotripsy', definition: 'A technology using sonic pressure waves to fracture arterial calcification, enabling vessel expansion for severely calcified PAD lesions' },
        { term: 'Chronic total occlusion', definition: 'Complete blockage of an artery over a long segment, requiring specialized crossing techniques for endovascular treatment' },
        { term: 'Subintimal angioplasty', definition: 'An endovascular technique that intentionally enters the subintimal space to cross chronic total occlusions when true lumen crossing fails' },
        { term: 'Acute limb ischemia', definition: 'A sudden decrease in limb perfusion threatening tissue viability, requiring emergency intervention within 6 hours' },
        { term: 'Catheter-directed thrombolysis', definition: 'Delivery of thrombolytic drugs directly into a clot via catheter to dissolve acute arterial occlusion' },
        { term: 'Hybrid revascularization', definition: 'Combined open surgical and endovascular procedures performed in a single setting to address multilevel PAD' }
      ],
      clinicalNotes: 'For acute limb ischemia, the most critical assessment is viability: can the limb be saved? Check motor function (wiggle toes) and sensory function (light touch). Loss of motor function (Rutherford IIb) indicates immediate threat and requires urgent revascularization. Loss of both motor and sensory function with muscle rigor (Class III) indicates irreversible ischemia where revascularization is futile and dangerous (reperfusion syndrome causing hyperkalemia, myoglobinuria, metabolic acidosis, multi-organ failure). Primary amputation is indicated for Class III. Heparin bolus (80 U/kg) should be given immediately upon diagnosis regardless of planned intervention.'
    },
    5: {
      level: 5,
      summary: 'Expert PAD management integrates precision medicine approaches to cardiovascular risk reduction, novel anti-inflammatory and antithrombotic strategies, biomarkers for disease progression, advanced imaging for plaque characterization, and health equity considerations in PAD outcomes.',
      explanation: 'The pathophysiology of PAD atherosclerosis involves complex interactions between lipid metabolism, inflammation, endothelial dysfunction, and thrombosis. Beyond traditional risk factors, emerging targets include: (1) Residual inflammatory risk: the CANTOS trial showed that canakinumab (anti-IL-1beta) reduced cardiovascular events in patients with elevated hsCRP, and the COLCOT trial demonstrated colchicine benefit after MI. Whether these anti-inflammatory strategies specifically benefit PAD is being studied. (2) Lipoprotein(a): elevated Lp(a) is an independent risk factor for PAD. Novel Lp(a)-lowering therapies (pelacarsen, olpasiran, lepodisiran) are in clinical trials and may reduce PAD progression and events. (3) PCSK9 inhibitors: the FOURIER trial subanalysis showed that evolocumab significantly reduced major adverse limb events (acute limb ischemia, major amputation) by 42% in PAD patients. This represents one of the most robust limb-specific benefits of any lipid-lowering therapy. (4) The VOYAGER PAD trial demonstrated that rivaroxaban 2.5 mg BID plus aspirin reduced acute limb ischemia and major amputation in patients after lower extremity revascularization, establishing a new standard for post-revascularization antithrombotic therapy. Advanced imaging for PAD includes: (1) Intravascular ultrasound (IVUS) for procedural guidance during complex endovascular intervention, particularly for optimizing stent expansion and detecting residual stenosis after atherectomy. (2) Optical coherence tomography (OCT) providing high-resolution vessel wall imaging for plaque characterization and stent apposition assessment. (3) Photoacoustic imaging combining laser light and ultrasound to identify lipid-rich plaques. (4) PET-CT with 18F-FDG or 18F-NaF for identifying actively inflamed or calcifying plaques that may be at risk for progression. Biomarkers for PAD include: cystatin C (renal function and cardiovascular risk), GDF-15 (cellular stress), galectin-3 (fibrosis), VEGF (angiogenesis), and circulating microRNAs (miR-210 for hypoxia, miR-126 for endothelial function). These are being studied for their ability to predict disease progression, response to exercise therapy, and amputation risk. Health equity in PAD is a critical concern. PAD disproportionately affects Black patients (2-3x higher prevalence than White patients), who also face higher amputation rates even after controlling for disease severity and comorbidities. The causes are multifactorial: higher prevalence of risk factors (diabetes, hypertension), later presentation with more advanced disease, reduced access to vascular specialists and revascularization, and implicit bias in clinical decision-making. Quality improvement initiatives targeting equitable access to limb salvage procedures, multidisciplinary wound care, and supervised exercise programs are essential. The BEST-CLI trial notably demonstrated that racial minorities were underrepresented, highlighting the need for more inclusive clinical trials. Exercise genomics is emerging: genetic variants in mitochondrial function genes (PGC-1alpha, AMPK pathway), angiogenesis genes (VEGF, HIF-1alpha), and skeletal muscle metabolism genes predict claudication severity and response to exercise therapy. Future personalized exercise prescriptions may incorporate genetic profiling to optimize training programs.',
      keyTerms: [
        { term: 'VOYAGER PAD trial', definition: 'A landmark trial demonstrating benefit of rivaroxaban plus aspirin for reducing limb events after lower extremity revascularization' },
        { term: 'Residual inflammatory risk', definition: 'The cardiovascular risk remaining after optimal lipid and blood pressure control, targeted by anti-inflammatory therapies like colchicine and IL-1 inhibitors' },
        { term: 'PCSK9 inhibitors for PAD', definition: 'Potent LDL-lowering agents that specifically reduce major adverse limb events by 42% in PAD patients per the FOURIER trial' },
        { term: 'Intravascular lithotripsy', definition: 'Sonic pressure wave technology for fracturing arterial calcification during endovascular procedures for calcified PAD' },
        { term: 'PAD health equity', definition: 'The recognition and effort to address disproportionate PAD burden and amputation rates in racial minorities and underserved populations' },
        { term: 'Exercise genomics', definition: 'The study of genetic variants influencing exercise capacity and response to supervised exercise therapy in PAD patients' }
      ],
      clinicalNotes: 'The comprehensive modern PAD management approach includes: (1) High-intensity statin (evolocumab/alirocumab if LDL not at goal, especially with Lp(a) elevation); (2) Rivaroxaban 2.5 mg BID + aspirin 81 mg for patients without high bleeding risk (COMPASS/VOYAGER evidence); (3) Supervised exercise therapy as first-line for claudication; (4) Aggressive diabetes management with consideration of SGLT2 inhibitors (cardiovascular and limb benefits); (5) Referral to multidisciplinary limb salvage team for CLTI; and (6) Attention to health equity in access to care. The goal is not just limb salvage but comprehensive cardiovascular event reduction, as most PAD patients die from MI or stroke rather than limb complications.'
    }
  },
  media: [],
  citations: [
    {
      id: 'gerhard-herman-2017',
      text: 'Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease. Circulation. 2017;135(12):e726-e779.',
      url: 'https://doi.org/10.1161/CIR.0000000000000471'
    },
    {
      id: 'bonaca-2020',
      text: 'Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization (VOYAGER PAD). N Engl J Med. 2020;382(21):1994-2004.',
      url: 'https://doi.org/10.1056/NEJMoa2000052'
    },
    {
      id: 'conte-2019',
      text: 'Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia (GVG). J Vasc Surg. 2019;69(6S):3S-125S.',
      url: 'https://doi.org/10.1016/j.jvs.2019.02.016'
    }
  ],
  crossReferences: [
    { contentId: 'vasculardisease', relationship: 'parent', description: 'PAD is a major component of systemic vascular disease caused by atherosclerosis' },
    { contentId: 'aorticaneurysm', relationship: 'related', description: 'AAA screening and PAD diagnosis both use vascular ultrasound and share atherosclerotic risk factors' }
  ],
  tags: {
    defined: ['peripheral-artery-disease', 'claudication', 'ankle-brachial-index', 'critical-limb-ischemia', 'revascularization', 'supervised-exercise', 'acute-limb-ischemia', 'endovascular'],
    source: ['AHA', 'ACC', 'SVS', 'ESC', 'ESVS']
  },
  createdAt: '2025-01-25',
  updatedAt: '2025-01-25',
  version: 2,
  status: 'published'
};
